MaxCyte stockholders elect three Class II directors and ratify CohnReznick as auditor

MAXCYTE, INC.

Patrick Balthrop, Cynthia Collins, and Stanley Erck elected as Class II directors with 39.8M, 46.9M, and 40.9M votes 'for' respectively.
Broker non-votes totaled 17.8M for each director nominee.
Ratification of CohnReznick LLP as auditor for FY 2026 passed with 70.2M 'for', 46.7K 'against', 30.3K abstentions.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MAXCYTE, INC. shareholders approved Ratification of the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-17

Exact text from the filing

Proposal 2 – Ratification of the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 70,227,193 46,732 30,256

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MAXCYTE, INC. shareholders approved Election of Class II Directors at the 2026-06-17 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-17

Exact text from the filing

Proposal 1 – Election of Class II Directors: Nominee For Withhold Broker Non-Votes Patrick Balthrop 39,760,379 12,728,826 17,814,976 Cynthia Collins 46,886,614 5,602,591 17,814,976 Stanley Erck 40,908,701 11,580,504 17,814,976

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

MAXCYTE, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-075211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.